Skip to main content

Erratum to: Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus

The Original Article was published on 13 January 2004

Text

In our recent article [1], we did not declare the patent rights related to stampidine technology. Since they may potentially be viewed as non-financial competing interests despite the fact our employer is a non-profit public charity, we are now providing the following supplemental information:

FMU, AOV and HET are employees of Parker Hughes Institute, which has applied for a patent for the use of stampidine in the treatment of haemorrhagic fever. Parker Hughes Institute currently holds patents for the use of stampidine in other clinical conditions, with FMU listed as an inventor.

References

  1. Uckun FU, Petkevich AS, Vassilev AO, Tibbles HE, Titov LP: Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus. BMC Infect Dis. 2004, 4: 1-10.1186/1471-2334-4-1.

    Article  PubMed  PubMed Central  Google Scholar 

Pre-publication history

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Fatih M Uckun.

Additional information

The online version of the original article can be found at 10.1186/1471-2334-4-1

Rights and permissions

Reprints and permissions

About this article

Cite this article

Uckun, F.M., Petkevich, A.S., Vassilev, A.O. et al. Erratum to: Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus. BMC Infect Dis 4, 14 (2004). https://0-doi-org.brum.beds.ac.uk/10.1186/1471-2334-4-14

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://0-doi-org.brum.beds.ac.uk/10.1186/1471-2334-4-14